What makes OPKO’s pipeline so valuable? First, OPKO has a Diagnostics Point-of-Care System. It is a diagnostic testing device that can be used in doctor’s offices, patient homes and emergency settings. Testing has shown to be extremely accurate, they only take 10 minutes to get results, and it is significantly cheaper than sending to the laboratory. The tests under development are: Prostate-Specific Antigen (Total PSA) Test, 4KScore Prostate Cancer Test, Vitamin D test, Testosterone Test, Alzheimer’s Disease test. Results of the early Alzheimer diagnostic test showed a diagnostic specificity of 100% as announced in July 2012.
OPKO’s diagnostic testing is extremely accurate based on IgG autoantibodies as disease specific-biomarkers. This discovery platform is also potentially applicable for next generation testing for diabetes, cancer, multiple sclerosis, Parkinson’s and Alzheimer’s. Other testing applications include fertility, menopause, D-dimer, BNP, CTnl, HIV, Hepatitis, Syphilis, folic acid and others.
In 2011, OPKO entered into a nonexclusive license agreement with Bristol Myers to further develop an Alzheimer’s disease diagnostic test. The benefit of this test is that not only will it assist in early diagnosis, it can also be used to test the effectiveness for the treatment of Alzheimer’s patients.
Each of these diagnostic tests represent billion dollar market opportunities. Imagine going to your doctor’s office where they have the ability to obtain your test results within 10 minutes without having to outsource to laboratories. Furthermore, the tests being performed are next generation tests that improve accuracy. According to OPKO’s website, approximately 700,000 prostate biopsies can be avoided per year with their biomarker test.